Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Lilly buys Alnara to move into enzyme drugs

05-Jul-2010

Related topics: Ingredients

Eli Lilly is moving into the enzyme replacement therapy (ERT) market with the acquisition of US biotechnology firm Alnara Pharmaceuticals.

The deal, terms of which were not disclosed, will add Alnara’s range of candidates to Lilly’s pipeline, include the non-porcine pancreatic enzyme replacement therapy (PERT) liprotamase which is being reviewed as a treatment for exocrine pancreatic insufficiency (EPI).

At present Lilly’s main research focus is on neuroscience, oncology and diabetetes, although the firm is keen to explore new therapeutic areas as Bryce Carmine president of Lilly BioMedicines explained.

He said the deal “provides Lilly with a promising entry into enzyme replacement therapy, an area with unmet medical needs as well as opportunities for novel compounds that give patients additional treatment options.”

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.